Pharnext’s pleotherapy shows synergistic effects with PXT-864 in Alzheimer’s disease through preclinical data
Pharnext SAS has announced the publication of preclinical results in Nature’s Scientific Reports for its lead pleodrug, PXT-864, in Alzheimer’s disease. These data further validate its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases.
In the publication titled, “Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy” by Ilya Chumakov, et al., data show that in two different rodent models, PXT-864, a combination of baclofen and acamprosate, demonstrated not simply additive but synergistic effect. Multiple induced markers of Alzheimer’s disease models were improved and / or normalized. Indeed, PXT-864 had synergistic and consistent effects on the following:
- Significant alleviation of induced cognitive deficits in the acquisition of long and short-term memory, novel objects recognition or learning and spatial working memory
- Protection of neurons from oxidative stress and death
- Preservation of the blood brain barrier that is also damaged in patients with Alzheimer’s disease
- Normalization in levels of pro-inflammatory factors associated with neuroinflammation
- Normalization of neuronal endogenous toxic factors levels and preservation of synaptic loss
Consistently with in vivo data, researchers also noted for PXT-864 a synergistic neuronal and vascular cellular protection in two in vitro models.
Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy, Ilya Chumakov, Serguei Nabirotchkin, Nathalie Cholet, Aude Milet, Aurélie Boucard, Damien Toulorge, Yannick Pereira, Esther Graudens, Sory Traoré, Julie Foucquier, Mickael Guedj, Emmanuel Vial, Noëlle Callizot, Rémy Steinschneider, Tangui Maurice, Viviane Bertrand, Catherine Scart-Grès, Rodolphe Hajj & Daniel Cohen, Nature’s Scientific Reports, doi:10.1038/srep07608, published 8 January 2015.